VLON
Vallon Pharmaceuticals, Inc. [VLON] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VLON Stock Summary
In the News
VLON Financial details
Company Rating
Sell
Market Cap
5.39M
Income
-13.5M
Revenue
0
Book val./share
0
Cash/share
0
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
26 Jul 2023
P/E
-25.9
Forward P/E
-
PEG
3.08
P/S
-
P/B
5798.81
P/C
-
P/FCF
-0.75
Quick Ratio
3.15
Current Ratio
3.15
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
-0.23
EPS next Y
-
EPS next Q
-
EPS this Y
-50.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-82.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.02%
Inst Trans
0.3%
ROA
-331%
ROE
-292%
ROC
-4.25%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.3803-0.4308
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
-
Volume
1.11M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
-1.14856
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.4
Change
-4.76%
VLON Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.01 | 0 | 0 | |
| Net income per share | -0.74 | -0.56 | -0.72 | -1.43 | -0.71 | |
| Operating cash flow per share | -0.41 | -0.43 | -0.55 | -1.27 | -0.7 | |
| Free cash flow per share | -0.41 | -0.43 | -0.55 | -1.27 | -0.7 | |
| Cash per share | 0.11 | 0.57 | 0.02 | 1.15 | 0.37 | |
| Book value per share | 0.03 | 0.48 | -0.22 | 0.89 | 0.23 | |
| Tangible book value per share | 0.03 | 0.48 | -0.22 | 0.89 | 0.23 | |
| Share holders equity per share | 0.03 | 0.48 | -0.22 | 0.89 | 0.23 | |
| Interest debt per share | 0 | 0.05 | 0.05 | 0.03 | 0 | |
| Market cap | 43.62M | 50.81M | 50.81M | 39.12M | 2.94M | |
| Enterprise value | 43.01M | 47.33M | 51.03M | 35.58M | -839.47K | |
| P/E ratio | -10.11 | -13.46 | -10.46 | -4.17 | -0.41 | |
| Price to sales ratio | 0 | 0 | 508.07 | 0 | 0 | |
| POCF ratio | -18.4 | -17.62 | -13.71 | -4.71 | -0.41 | |
| PFCF ratio | -18.38 | -17.62 | -13.7 | -4.71 | -0.41 | |
| P/B Ratio | 285.2 | 15.81 | -34.94 | 6.72 | 1.26 | |
| PTB ratio | 285.2 | 15.81 | -34.94 | 6.72 | 1.26 | |
| EV to sales | 0 | 0 | 510.34 | 0 | 0 | |
| Enterprise value over EBITDA | -9.97 | -15.64 | -10.83 | -3.9 | 0.13 | |
| EV to operating cash flow | -18.14 | -16.41 | -13.77 | -4.28 | 0.12 | |
| EV to free cash flow | -18.12 | -16.41 | -13.76 | -4.28 | 0.12 | |
| Earnings yield | -0.1 | -0.07 | -0.1 | -0.24 | -2.45 | |
| Free cash flow yield | -0.05 | -0.06 | -0.07 | -0.21 | -2.43 | |
| Debt to equity | 0 | 0.11 | -0.23 | 0.03 | 0 | |
| Debt to assets | 0 | 0.08 | 0.35 | 0.02 | 0 | |
| Net debt to EBITDA | 0.14 | 1.15 | -0.05 | 0.39 | 0.57 | |
| Current ratio | 1.31 | 4.86 | 0.3 | 3.32 | 2.29 | |
| Interest coverage | 0 | 0 | -140.82 | -578.69 | -266.46 | |
| Income quality | 0.55 | 0.83 | 0.77 | 0.89 | 1.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 11.81 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 37.07 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | -0.02 | 0 | 0 | |
| Capex to depreciation | -3.6 | 0 | -0.03 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 1.54 | 0 | 0 | |
| Graham number | 0.66 | 2.45 | 1.87 | 5.36 | 1.92 | |
| ROIC | -28.21 | -0.88 | 5.72 | -1.52 | -3.04 | |
| Return on tangible assets | -6.75 | -0.88 | -5.08 | -1.13 | -1.74 | |
| Graham Net | 0.02 | 0.41 | -0.34 | 0.76 | 0.19 | |
| Working capital | 151.35K | 3.11M | -1.55M | 5.68M | 2.34M | |
| Tangible asset value | 152.94K | 3.21M | -1.45M | 5.82M | 2.34M | |
| Net current asset value | 151.35K | 2.86M | -1.74M | 5.61M | 2.34M | |
| Invested capital | 0 | 0.11 | -0.23 | 0.03 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 266.47K | 736.16K | 1.07M | 947.5K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -28.2 | -1.17 | 3.34 | -1.61 | -3.08 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.02 | -0.22 | -0.01 | 0 | 0 | |
| Operating cash flow per share | -0.15 | -0.14 | -0.01 | 0 | 0 | |
| Free cash flow per share | -0.15 | -0.14 | -0.01 | 0 | 0 | |
| Cash per share | 0.43 | 0.37 | 0 | 0 | 0 | |
| Book value per share | 0.29 | 0.23 | 0 | 0 | 0 | |
| Tangible book value per share | 0.29 | 0.23 | 0 | 0 | 0 | |
| Share holders equity per share | 0.29 | 0.23 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 3.45M | 2.94M | 162.51M | 967.11M | 1.65B | |
| Enterprise value | -1.28M | -839.47K | 160.84M | 962.36M | 1.65B | |
| P/E ratio | -2.97 | -0.34 | -16.74 | -35.84 | -193 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.86 | -2.15 | -70.32 | 0 | -772.01 | |
| PFCF ratio | -1.86 | -2.15 | -70.32 | 0 | -772.01 | |
| P/B Ratio | 1 | 1.26 | 5.24K | 239.5 | 740.81 | |
| PTB ratio | 1 | 1.26 | 5.24K | 239.5 | 740.81 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0.8 | 0.72 | -68.47 | -162.18 | -675 | |
| EV to operating cash flow | 0.69 | 0.61 | -69.6 | 0 | -770.39 | |
| EV to free cash flow | 0.69 | 0.61 | -69.6 | 0 | -770.39 | |
| Earnings yield | -0.08 | -0.74 | -0.01 | -0.01 | 0 | |
| Free cash flow yield | -0.54 | -0.47 | -0.01 | 0 | 0 | |
| Debt to equity | 0 | 0 | 0 | 0.01 | 0.01 | |
| Debt to assets | 0 | 0 | 0 | 0.01 | 0.01 | |
| Net debt to EBITDA | 2.95 | 3.26 | 0.71 | 0.8 | 1.42 | |
| Current ratio | 2.64 | 2.29 | 3.15 | 3.49 | 2.01 | |
| Interest coverage | -702 | -53.27 | -148.75 | 6.35 | -406.5 | |
| Income quality | 1.79 | 0.87 | 0.96 | 0 | 1 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.39 | 1.06 | 0 | 0.01 | 0 | |
| ROIC | -0.11 | -0.82 | -77.77 | -1.44 | -1.07 | |
| Return on tangible assets | -0.05 | -0.53 | -1.16 | -1.2 | -0.49 | |
| Graham Net | 0.25 | 0.19 | 0 | 0 | 0 | |
| Working capital | 3.46M | 2.34M | 1.14M | 3.99M | 2.19M | |
| Tangible asset value | 3.46M | 2.34M | 31K | 4.04M | 2.23M | |
| Net current asset value | 3.46M | 2.34M | -401K | 3.99M | 2.19M | |
| Invested capital | 0 | 0 | 0 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.5M | 1.08M | 752.5K | 417.5K | 647.5K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.08 | -0.93 | -78.29 | -1.67 | -0.96 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
VLON Frequently Asked Questions
What is Vallon Pharmaceuticals, Inc. stock symbol ?
Vallon Pharmaceuticals, Inc. is a US stock , located in Philadelphia of Pa and trading under the symbol VLON
What is Vallon Pharmaceuticals, Inc. stock quote today ?
Vallon Pharmaceuticals, Inc. stock price is $0.4 today.
Is Vallon Pharmaceuticals, Inc. stock public?
Yes, Vallon Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Market Capitalization 5.39M
- Employee 2
- CEO Mr. David C. Baker
- Headquarters Philadelphia,PA,US
- IPO Date 2021-02-10
-
Website
https://www.vallon-pharma.com 
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
